Pharmacologic treatment of atrophic age-related macular degeneration.
OBJECTIVE
To review and compare the various therapeutic platforms, investigational drugs, and clinical trials targeting geographic atrophy in age-related macular degeneration.


RESULTS
Investigational agents based on hypothesized causes are being developed to treat geographic atrophy. These platforms are designed to attack the disease on several different fronts.


CONCLUSIONS
As knowledge of geographic atrophy pathophysiology advances, targeted pharmacotherapies may well be able to mitigate the retinal damage and vision loss associated with geographic atrophy.
Mata
Nathan L
NL
Sirion Therapeutics, Inc., Tampa, Florida, USA.
Vogel
Roger
R
D057092:Geographic Atrophy / Q000188:drug therapy* / Q000503:physiopathology; D006801:Humans; D008268:Macular Degeneration / Q000188:drug therapy* / Q000503:physiopathology